Menu
1 min read · estimated
APPROVED USE
What FDA approved
Limits pembrolizumab with platinum and fluoropyrimidine chemotherapy in locally advanced or metastatic esophageal or qualifying GEJ carcinoma that cannot be treated with resection or definitive chemoradiation to tumors with PD-L1 CPS of at least 1.
LAMPGEN ANALYSIS
Why it matters
The first-line combination label now requires PD-L1 expression; the separate post-systemic monotherapy indication retains its higher threshold.
What research teams should watch
Confirm the anatomic site and PD-L1 score and apply the threshold specific to the intended regimen.
PRIMARY RECORDS